This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
|Treatment||Nivolumab, rucaparib, Placebo Oral Tablet, Placebo IV Infusion|
|Clinical Study Identifier||NCT03522246|
|Sponsor||Clovis Oncology, Inc.|
|Last Modified on||4 November 2020|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.